CT derived body composition index analysis in metastatic NET patients treated with mTOR inhibitor

#3714

Introduction: Neuroendocrine tumors (NETs) are rare neoplasms frequently characterized by an upregulation of the mammalian rapamycin targeting (mTOR) pathway resulting in uncontrolled cell proliferation. The mTOR pathway is also involved in skeletal muscle protein synthesis and in adipose tissue metabolism. Everolimus inhibits the mTOR pathway, resulting in blockade of cell growth and tumor progression.

Aim(s): The aim of this study is to investigate the role of body composition indexes in patients with metastatic NETs treated with everolimus which is an mTOR inhibitor.

Materials and methods: Data of 26 patients with locally advanced (unresectable) or metastatic NET who had received treatment with everolimus were retrospectively collected from our record. The skeletal muscle index [SMI] and adipose tissue indexes were assessed by measuring on a computed tomography (CT) scan the cross-sectional area at L3 at baseline and at the first radiological assessment after the start of treatment. The body mass index (BMI) was assessed at baseline. The median progression-free survival (PFS) was 8 months.

Conference:

Presenting Author: Fatima A

Authors: Fatima A,

Keywords: mTOR, metastatic NET, body composition index, skeletal muscle protein,